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Measurement tools of resource use and quality of life in clinical trials for dementia or 
cognitive impairment interventions: a systematically conducted narrative review 
 
Abstract 
 
Objective: Knowledge is limited about the standardised instruments used to collect resource 
use and quality of life data alongside trials of dementia interventions. This review aimed to 
identify the trials using such instruments in order to guide the design of future trial-based 
cost-effectiveness studies. 
 
Methods: In accordance with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses Statement, this review examined all original, peer-reviewed research in major 
databases and general searches published until June 2017, including randomised clinical 
trials, pilot studies or feasibility studies about interventions for older adults with dementia or 
cognitive impairment.  
 
Results: Forty-one studies were identified. Only 8 collected the resource use data using 
adapted Client Service Receipt Inventory (CSRI), Resource Use Inventory (RUI), cost diary 
or study-specific questionnaire. Quality of life was assessed using a wide range of 
instruments. The most frequently used dementia-specific instrument was Quality of Life in 
$O]KHLPHU¶V Disease (QOL-AD) and Dementia Quality of Life questionnaire (DEMQOL). 
Among the generic measures, EuroQol 5-dimentison (EQ-5D) was mostly used to collect 
health utility data and Short Form surveys (SF-36 or SF-12) were widely to measure general 
health.  
 
2 
 
Conclusions: Several useful resource use and quality of life measurement instruments have 
been identified by this review. For resource use, CSRI was mostly used, but no studies have 
used Resource Utilisation in Dementia (RUD); for quality of life, we recommend the 
inclusion of dementia-specific DEMQOL, generic SF-12, and health utility EQ-5D-5L, based 
on both self- and proxy-report.   
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Introduction 1 
 2 
Dementia is a growing public health problem (Scholzel-Dorenbos et al., 2007) and the 3 
worldwide cost of dementia has been estimated to exceed those of other chronic diseases 4 
(Wimo et al., 2010). Some new treatments have been developed, which could contribute to 5 
the care of people with dementia and their families in a wide range of domains (Moniz-Cook 6 
et al., 2008a). Given the finite health care budget, economic evaluations aiming to support 7 
decision making about these new treatments in dementia are essential. Ideally, these 8 
evaluations should be based on long-term clinical trial results that capture the benefits and 9 
costs of the intervention (Hughes et al., 2016).  10 
 11 
Cost-utility analysis is the most widely used form of economic evaluation. In such analysis, 12 
quality-adjusted life year (QALY) is routinely used as the summary measure of health 13 
outcomes, which takes both the quantity and quality of life into account. In dementia 14 
research, Quality of Life (QoL) has been recognised as an important measure as the clinical 15 
measures. Several instruments have specifically been developed to assess QoL in dementia 16 
(Scholzel-Dorenbos et al., 2007, Bowling et al., 2015). According to the most recent 17 
systematic review (Bowling et al., 2015), more than 10 QoL measures were identified and 18 
properties assessed, but this review was limited to disease-specific QoL measures only, and 19 
such measures may not be used directly to generate health utility scores for QALYs 20 
calculations in cost-utility analysis. With regard to the QoL measures used in clinical trials of 21 
dementia, a systematic review done by Schölzel-Dorenbos et al (Scholzel-Dorenbos et al., 22 
2007) found only 3 studies and 2 QoL scales. To our knowledge, this is the only review of 23 
this type. Following this review, many new QoL instruments were developed and widely 24 
used, including the Dementia Quality of Life questionnaire (DEMQOL) (Smith et al., 2005). 25 
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But whether these instruments are appropriate for data collection in clinical trials is still not 1 
clear. 2 
 3 
Another important component of cost-utility analysis is resource use. According to the Good 4 
Research Practices Task Force for cost-effectiveness analysis alongside clinical trials 5 
developed by the International Society for Pharmacoeconomics and Outcomes Research 6 
(ISPOR) (Ramsey et al., 2015), instruments are recommended for cost data collection to 7 
improve the quality and uniformity of data generated from trials. But it is not practical to 8 
have standardised instruments to measure costs since the range of services to be costed in an 9 
economic evaluation depends a lot on the type of intervention and the data sources available. 10 
To address this issue, some investigators use questionnaires that could be tailored to meet the 11 
needs of each individual study. A frequently used questionnaire is the client service receipt 12 
inventory (CSRI) and it has been widely used and adapted to collect data in some 13 
observational studies in dementia (McCrone, 2009). Alternatively, there is one standardised 14 
and dementia-specific tool available to collect resource use data, Resource Utilisation in 15 
Dementia (RUD) instrument (Wimo et al., 2013). It has been used in clinical drug trials and 16 
observational studies (Wimo et al., 2003, Wimo and Winblad, 2003). But there is a lack of 17 
information about the use of RUD in clinical trials, especially for non-pharmacological 18 
interventions, and whether there are other instruments available to collect resource use data in 19 
such trials is yet unknown. 20 
 21 
Therefore, this review aimed to identify the trials using resource use and QoL measures to 22 
collect data in clinical trials about dementia or cognitive interventions and then describe and 23 
compare these instruments in terms of their performance in trials, in order to provide a 24 
5 
 
foundation for the study design of future clinical trial-based cost-utility analysis of dementia 1 
or cognitive interventions.  2 
 3 
Methods 4 
 5 
In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 6 
(PRISMA) Statement (Moher et al., 2009), this review followed the published protocol (Yang 7 
et al., 2017) and consisted of acquiring, extracting and assessing the data (Figure 1). 8 
 9 
Eligibility criteria 10 
The eligibility criteria were: 11 
x Population - older adults with dementia or cognitive impairment 12 
x Intervention - all types of interventions, both drug and nondrug therapies 13 
x Comparator - no intervention or the usual care 14 
x Outcomes - measurement and reporting of QoL, or resource use or both  15 
x Study type - randomised clinical trial (RCT), or feasibility study or pilot study 16 
 17 
The definition of µolder patients with dementia or cognitive impairment¶ used in this review 18 
was based on each individual study if it described its population as being old adults with 19 
dementia or cognitive impairment. Quality of life is an abstract and broad concept including 20 
physical function, perceptions of well-being, satisfaction, and sense of self-worth. It has to be 21 
assessed by using questionnaires to survey the relevant subjects. Both the profile-based and 22 
preference-based QoL instruments were eligible for this review. An instrument is profile-23 
based if it measures different domains of health-related QoL and generates a score for each of 24 
these domains, e.g. 36-item Short-Form (SF-36). If an instrument measures the utility of 25 
6 
 
certain health outcomes, the instrument is preference-based, e.g., the EuroQol 5-dimension 1 
(EQ-5D) (Rabin and de Charro, 2001), which could provide a single overall health utility 2 
score for QALYs calculation. Given the aim of this review was to guide cost-utility analysis 3 
study design, health utility, quality-adjusted life years and QALYs were also used as the 4 
search terms. We included RCT or pilot/feasibility studies using RCT design, which were 5 
small-scale preliminary studies conducted prior to the full RCTs in order to evaluate 6 
feasibility, effects, etc.  7 
 8 
Search strategy 9 
The following major databases (Ovid Medline, PsycINFO, EMBASE, CINAHL, Cochrane 10 
Databases of Systematic Reviews, Web of Science and Scopus) were searched in September 11 
2016 and the searches were re-run before the final analyses in June 2017. A hand search of 12 
the references of included articles and general search, e.g. Google Scholar, were also 13 
conducted to identify potential relevant studies. Key terms were determined through 14 
discussion between authors. The search strategies were created specifically for each database 15 
using relevant index and free text terms (see Appendix 1 for the terms used in Ovid Medline). 16 
Studies were eligible regardless of the language or date of publication, but the abstract was 17 
available in English. 18 
 19 
Article selection 20 
All results were exported into Endnote X7 software (Thomson Reuters, 2016). After dropping 21 
duplicates, all the titles and abstracts of the studies retrieved were imported to an Excel 22 
spreadsheet (Microsoft Corporation, 2010). The first author (F.Y.) screened all the abstracts 23 
to rule out the literature reviews, meta-analyses, clinical guidelines, study protocols, 24 
editorials, letters, commentaries, case reports, and conference proceedings that were not 25 
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recognised as original articles. Two authors (F.Y. and B.G.) independently screened the titles 1 
and abstracts of the remaining articles against the inclusion criteria. If a title or abstract 2 
suggested that the trial was eligible, or if there was insufficient information to make a 3 
decision, the full-text was retrieved and assessed for eligibility independently by both 4 
authors. Discrepancies were resolved through discussion or adjudication by a third author 5 
(P.D.) if necessary.  6 
 7 
Data extraction 8 
We developed a standardised excel sheet to extract data from the included studies, including 9 
publication characteristics, participant characteristics, intervention characteristics, and 10 
instrument characteristics.  11 
 12 
Data synthesis 13 
First, the characteristics of included studies were tabulated. Second, we summarised the 14 
frequency of each instrument used in the trials. Third, the characteristics of each QoL 15 
instrument were described and tabulated, using a table adapted from the one used in a review 16 
of dementia-specific QoL scales (Bowling et al., 2015), including instrument, conceptual 17 
basis, patient/proxy report, patient population, subscales, items, response options and scoring.  18 
 19 
Results  20 
 21 
Search results 22 
The searches yielded 2527 records. After removing duplicates, the title and abstract of 1089 23 
unique records were screened. 65 were sought for full-text screening and 41 studies were 24 
eligible for inclusion.  25 
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Study characteristics  1 
The studies were published between 2000 and 2017 and conducted in 15 countries/regions, 2 
most frequently in the US, the UK and Australia (Table 1). Most of studies were RCTs 3 
(73.2%) and nearly half of the studies included both dementia and mild cognitive impairment 4 
patients (46.3%). Majority studies aimed to assess the non-pharmacological interventions 5 
(85.4%).  6 
 7 
Resource use measure 8 
Among the 41 studies included, 8 studies collected resource use data. Healthcare costs were 9 
calculated by multiplying the number of units of each type of service received by the unit cost 10 
of that service estimated from published reports and administrative datasets and summing the 11 
products across different services. Resource use data were collected using multiple 12 
instruments, including Client Service Receipt Inventory (CSRI), Resource Use Inventory 13 
(RUI), cost diary and informal care survey, and a study-specific questionnaire developed 14 
specifically for that study.  15 
 16 
Client Service Receipt Inventory (CSRI)  17 
There were 5 studies using adapted CSRI to collect resource use data (Knapp et al., 2006, 18 
Woods et al., 2012, Banerjee et al., 2011, Romeo et al., 2013, D'Amico et al., 2015, Knapp et 19 
al., 2016, Howard et al., 2012). All studies were conducted in the UK, ranging from mild to 20 
severe dementia. The CSRI was developed by Knapp and Beecham in the mid-1980s to 21 
collect detailed information on healthcare services received, medication, and wider carer 22 
economic impacts. It has five sections: background client information; accommodation and 23 
living situation; employment history, earnings and benefits; a record of services and unpaid 24 
cares (PSSRU). 2QHRI WKH&65,¶VJUHDWHVW VWUHQJWKV LV LWVDGDSWDELOLW\ A large number of 25 
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versions of it have been produced to suit the needs of each individual study, and it has been 1 
extensively used in studies of mental health and dementia. The CSRI is usually completed 2 
through interviews with patients and their caregivers.  3 
 4 
Resource Use Inventory (RUI) 5 
In the Finnish study for people with mild cognitive impairment (Kivipelto et al., 2013), 6 
utilisation of health resources were estimated using register data and questionnaire data. The 7 
questionnaire used in this study was the Resource Use Inventory (RUI) (Sano et al., 2006), 8 
which was developed to capture resource utilisation and costs in populations with 9 
$O]KHLPHU¶VGLVHDVH7KH58,ZDVFRPSOHWHGE\WKHSDWLHQWDQGWKHFDUHUWRJHWKHU,W10 
consisted of 9 questions to document the use of direct medical services and nonmedical care. 11 
The RUI also includes questions to capture the time caregivers spend providing care to the 12 
patients and the time use of the patients by participating in paid and volunteer work.  13 
 14 
Cost diary and survey 15 
In a study for Dutch dementia patients (Wolfs et al., 2009), resource use data were estimated 16 
using the hospital and pharmacy datasets, the informal care surveys, and cost diaries. The 17 
informal care survey was developed by van den Berg et al for the measurement and valuation 18 
of informal care (van den Berg et al., 2005). In this survey, informal caregivers were asked to 19 
indicate the average time spent on different informal care tasks per week, at baseline and at 20 
follow-ups. The carers were also asked to complete the cost diaries at both baseline and 21 
follow-ups to determine the costs made outside the hospital that could not be gathered from 22 
WKHKRVSLWDORUSKDUPDFLVW¶VUHJLVWUDWLRns. Cost diaries are an accepted method to assess 23 
resource use in cost-effectiveness studies (Goossens et al., 2000).  24 
10 
 
Study-specific questionnaire 1 
In the cost-EHQHILWDQDO\VLVRIGUXJWKHUDSLHVIRURXWSDWLHQWVZLWK$O]KHLPHU¶Vdisease done in 2 
US (Rosenheck et al., 2007), a questionnaire was developed for this study and was completed 3 
by the caregiver every month to document the healthcare service use, including hospital 4 
stays, outpatient services, community supports and other related services.  5 
 6 
QoL measure 7 
The quality of life was assessed using a wide range of instruments across the studies (Table 8 
2). We noted 15 different QoL instruments, with 5 dementia-specific and 10 generic. Multiple 9 
measures were used in several studies.  10 
 11 
Dementia-specific measure 12 
The dementia-specific instruments identified were: 4XDOLW\ RI /LIH LQ $O]KHLPHU¶V 'LVHDVH13 
(QOL-AD) (n=22), Dementia Quality of Life questionnaire (DEMQOL) (n=4), Quality of 14 
Life in Late-stage Dementia (QUALID) (n=3), Alzheimer's Disease Related Quality of Life 15 
(ADRQL) (n=2), and Dementia Quality of Life Instrument (DQOL) (n=1). The 16 
characteristics of these instruments were summarised in Table 3.  17 
 18 
4XDOLW\RI/LIHLQ$O]KHLPHU¶V'LVHDVH42/-AD) 19 
QOL-AD was designed to measure the quality of life among individuals living with 20 
$O]KHLPHU¶VGLVHDVH(Logsdon et al., 1999). It includes both self-rating version with 13 items 21 
and proxy-rating (by family carer or staff) version with 15 items. The items ask the 22 
patient/proxy to score aspects of physical health, energy level, mood, living situation, 23 
memory, family, marriage, friends, self, ability to do chores and things for fun, money, and 24 
life as a whole using 4-point scales (poor/fair/good/excellent). Both the patient and proxy 25 
11 
 
versions have been used in the identified studies. QOL-AD score ranges from 13 to 52 for 1 
patient version and 15 to 60 for proxy version, with higher scores representing better quality 2 
of life. It is recommended by the European consensus on outcome measures for psychosocial 3 
interventions in dementia (Moniz-Cook et al., 2008b). 4 
 5 
Dementia Quality of Life questionnaire (DEMQOL) 6 
The DEMQOL is a 28-item instrument, which covers five domains of quality of life (daily 7 
activities and looking after self; health and well-being; cognitive functioning; social 8 
relationships; self-concept), aiming to assess QoL in people with mild to moderate dementia 9 
(Smith et al., 2005). A proxy version was developed for caregivers, DEMQOL-Proxy, with 10 
31 items. A 4-point Likert scale (a lot/quite a bit/a little/not at all) is used to collect responses 11 
to each item. A Likert scale measures attitudes and behaviours using answer choices that 12 
range from one extreme to another and thus allows the respondent to uncover degrees of 13 
opinion. In the eligible studies, DEMQOL and DEMQOL-Proxy were used together with the 14 
exception of DEMQOL-Proxy for people with moderate to severe dementia (Knapp et al., 15 
2016). Score ranges from 28 to 112 for DEMQOL and 31 to 124 for DEMQOL-Proxy. 16 
Higher scores indicate better QoL. In addition, health utility values can be generated from 17 
DEMQOL (DEMQOL-U) and DEMQOL-Proxy (DEMQOL-Proxy-U) to enable the QALYs 18 
calculation for cost-utility analysis (Mulhern et al., 2013). This approach has been used in the 19 
economic evaluation study of a maintenance cognitive stimulation therapy for people with 20 
mild-to-moderate dementia in the UK (D'Amico et al., 2015).  21 
 22 
Quality of Life in Late-stage Dementia (QUALID) 23 
QUALID was designed specifically for use with people with late-stage dementia in 24 
institutional settings and it measures 11 observable behaviours including both positive and 25 
12 
 
negative dimensions of observable activity and emotional states. The assessments are based 1 
on concrete observable behaviours, so it is usually completed by nursing staff. Items are rated 2 
on a 5-point Likert scale which captures the frequency of each item and score ranges from 11 3 
to 55 with lower scores representing better QoL. The QUALID has been recommended by 4 
the Swedish Dementia Centre to estimate QoL in dementia patients (Nordgren and 5 
Engstroem, 2014). 6 
 7 
Alzheimer's Disease Related Quality of Life (ADRQL)  8 
ADRQ/ZDVGHYHORSHGIRUSDWLHQWVZLWK$O]KHLPHU¶VGLVHDVHWRDVVHVVPXOWLGLPHQVLRQDO9 
domains of QoL in dementia that patients, caregivers, and experts identified as important 10 
(Rabins et al., 1999). It has 48 items, grouped into 5 domains, measuring the observable 11 
EHKDYLRXUVDQGDFWLRQV,WLVXVHGIRUIDPLO\FDUHJLYHUV¶SUR[\UDWLQJVRIWKHSDWLHQW¶V4R/A 12 
4-point Likert scale is used in ADRQL (not at all/not very/somewhat/very much) and scores 13 
are calculated using a preference-based weighting approach, which means that weights for 14 
QoL indicators vary according to the importance of the domain. Higher scores reflect better 15 
quality of life.  16 
 17 
Dementia Quality of Life Instrument (DQOL)   18 
DQOL contains 30 items, forming 5 subscales related to QoL: aesthetics, positive affect, 19 
absence of negative affect, belonging, and self-esteem (Brod et al., 1999). It was developed 20 
through literature review and consultation with expert panels composed of dementia patients, 21 
caregivers, and professional care providers (Ready and Ott, 2003). Items are rated on one of 22 
two 5-point Likert scales (ranging from not at all to a lot, and never to very often) and DQOL 23 
yields scores on 5 subscales. Lower scores on µnegative affect¶ and higher scores on other 24 
subscales indicate worse QoL.  25 
13 
 
Generic QoL measure 1 
Among the 10 generic QoL measures, 3 health utility measures were included: EQ-5D (n=5), 2 
15-dimension (n=1) and Health Utilities Index Mark 3 (HUI3) (n=1). Other generic 3 
instruments were: 36-item Short-Form (SF-36) (n=2), 12-item Short-Form (SF-12) (n=1), 12-4 
item General Health Questionnaire (GHQ-12) (n=1), 15-item Quality of Life Scales (QOLS) 5 
(n=1), Anamnestic Comparative Self-Assessment Scale (ACSA) (n=1), QOL Face Scale 6 
scores (n=1), and Quality of Life Assessment-Patient (QLA-P) (n=1).  7 
 8 
EuroQol 5-dimension (EQ-5D) 9 
The EQ-5D is a generic, utility-based QoL instrument. It can be simply administered to 10 
patients in the form of a self-completed questionnaire. All the identified studies used the 3-11 
level version (EQ-5D-3L), which consists of 5 domains (mobility, self-care, usual activities, 12 
pain and discomfort, and anxiety and depression) and 3 levels for each domain (no 13 
problems/some problems/extreme problems or unable). According to the domains and levels, 14 
EQ-5D-3L yields 243 potential health states, each of which is assigned a utility weight, range 15 
from -0.594 to 1 using a utility scoring function derived from the UK general population. 16 
High scores represent higher utility. Among the 5 studies using EQ-5D as an outcome 17 
measure, 3 studies included both self-rated and proxy-rated EQ-5D (Romeo et al., 2013, 18 
D'Amico et al., 2015, Hoffmann et al., 2016). The EQ-5D is recommended by the National 19 
Institution for Health and Care Excellence (NICE) in England to be used in economic 20 
evaluations of health-care interventions (NICE, 2013).  21 
 22 
15-dimension (15D)  23 
15D is a generic health utility QoL measure (Sintonen, 2001). It consists of 15 dimensions 24 
(mobility, vision, hearing, breathing, sleeping, eating, speech, excretion, usual activities, 25 
14 
 
mental function, discomfort and symptoms, depression, distress, vitality, and sexual activity) 1 
with 5 ordinal levels. Similar to EQ-5D, a single index score measure can be calculated from 2 
the health state descriptive system by using a set of utility weights. The index score ranges 3 
from 0 to 1 (Sintonen, 2001). The 15D scores have been shown to be reliable, sensitive and 4 
responsive to change, and valid for deriving QALYs (Sintonen, 2001). In the identified study 5 
(Kivipelto et al., 2013), it was measured directly from the participants, who were at risk of 6 
cognitive decline. 7 
 8 
Health Utilities Index Mark 3 (HUI3) 9 
HUI3 is also a generic health utility measure consisting of eight attributes: hearing, vision, 10 
speech, ambulation, dexterity, emotion, cognition, and pain. Each attribute has multiple 11 
functioning levels. To calculate the HUI3 score, a utility scoring function derived from a 12 
representative sample of the Canadian general population is used. Score ranges from -0.36 to 13 
1 with higher scores reflecting better health (Wee et al., 2007). In the study about dementia 14 
interventions (Rosenheck et al., 2007), HUI3 ZDVDGPLQLVWHUHGWRFDUHJLYHUVWRUDWHSDWLHQWV¶15 
QoL, supplemented by several disease-specific measures (Rosenheck et al., 2007). 16 
 17 
Short Form Surveys (SF-36 and SF-12) 18 
SF-36 is the most widely used profile-based QoL measure, which includes eight areas: 19 
physical functioning, role functioning, bodily pain, general health, vitality, social functioning, 20 
role-emotional functioning, and mental health. Two summary scores, physical component 21 
summary (PCS) and mental component summary (MCS), can be calculated to indicate the 22 
SDWLHQWV¶4R/, ranging from 0 to 100 with higher scores representing better health. SF-12 is 23 
the abridged version of SF-36, and it has been used increasingly because of its lower burden 24 
to respondents and similar measurement properties as its longer version (Ware et al., 1996). 25 
15 
 
In the trials identified (Kivipelto et al., 2013, Gates et al., 2014, Kwok et al., 2013), both 1 
instruments were used to collect data from patients with mild cognitive impairment directly at 2 
baseline and follow-ups. 3 
 4 
12-item General Health Questionnaire (GHQ-12) 5 
GHQ-12 measures two main areas with 12 items: the inability to carry out normal functions 6 
and the appearance of new and distressing phenomena. In the study identified from this 7 
review (Graff et al., 2007) , GHQ-12 was used to ask patient to rate their own QoL. The score 8 
ranges from 0 to 36 with lower scores indicating better health.  9 
 10 
15-item Quality of Life Scales (QOLS)  11 
QOLS has 15 items that measures five domains of life: material and physical well-being; 12 
relationships with other people; social, community, and civic activities; personal development 13 
and fulfilment; and recreation (Burckhardt and Anderson, 2003). The QOLS scores range 14 
from 16 to 112 with higher scores indicating better quality of life (Burckhardt and Anderson, 15 
2003). It was used to collect data from individuals with mild cognitive impairment directly 16 
(Gates et al., 2014). 17 
 18 
Anamnestic Comparative Self-Assessment Scale (ACSA)  19 
ACSA is a ten-stage anchor scale for a global assessment of present quality of life defined in 20 
WHUPVRIWKHµEHVWWLPH¶YHUVXVWKHµZRUVW WLPH¶LQlife. A higher quality of life is reflected by 21 
an improvement in the global scale score. It was completed by the patients themselves at both 22 
baseline and follow-up (Walter et al., 2007).  23 
 24 
16 
 
QOL Face Scale 1 
QOL Face Scale is a 9-choice picture format with a score range of 1-9 (worst=1, best=9, from 2 
frowning to smiling faces) assessing the degree of general happiness in current daily life. It 3 
was used to ask the caregivers to answer these questions on behalf of the patients with 4 
dementia (Nakatsuka et al., 2015).  5 
 6 
Quality of Life Assessment-Patient (QLA-P)  7 
QLA-P is a rating scale completed by caregivers to assess broad areas of patient¶V quality of 8 
life. The original version includes 10 categories (working, leisure, eating, sleeping, social 9 
contact, earning, parenting, loving, environment, and self-acceptance). In the identified study 10 
(Davis et al., 2001), the scale was adapted to increase its relevance to patients with 11 
$O]KHLPHU¶VGLVHDVH. Each category is rated using an anchor points (0 and 50), with higher 12 
scores reflecting higher QoL. 13 
 14 
Discussion 15 
 16 
In view of the need for economic assessment of dementia interventions, collecting 17 
information on resource use and quality of life using the standardised instruments in clinical 18 
trials is important to ensure high quality data for further cost-effectiveness analysis. In this 19 
review, we examined 41 studies to identify such instruments used in dementia.  20 
 21 
The resource use instruments were seldom used in previous published RCTs or feasibility 22 
studies. CSRI and RUI were identified in this review, but the dementia-specific resource use 23 
instrument, RUD, was not included. Wimo et al (Wimo et al., 2013) have done a head-to-24 
head comparison of RUD with other resource use instruments, including CSRI and RUI, and 25 
17 
 
concluded that informal care is the key resource of the RUD instrument and is probably the 1 
only item that will not be available from other sources. The inclusion of informal care in 2 
RUD could make better estimates of the resource used. Also, RUD is suitable for 3 
multinational study as the same resource items should be used across different translations to 4 
enable comparison of costs of care across countries. A short version of RUD, RUD Lite 5 
(Wimo et al., 2013), is available and it is more appropriate if the caregiver resource use is not 6 
central to the study.  7 
 8 
For QoL measurement, 5 dementia-specific instruments were identified. These instruments 9 
differ in many aspects including conceptual basis, applicability and psychometric properties. 10 
QOL-AD measures a broader range of QoL validated during focus groups with patients and 11 
carers while DEMQOL focuses on the health-related QoL, which relates only to areas of QoL 12 
affected by a health condition. Both instruments have been shown to have good psychometric 13 
properties for individuals with mild to moderate dementia (Logsdon et al., 2002, Smith et al., 14 
2005). QUALID was designed for people with late-stage dementia in institutional settings, so 15 
it may have limited applicability to those with mild to moderate dementia. ADRQL was 16 
developed based on the assumption that the FDUHJLYHUVDUHEHVW WRDVVHVV WKHSDWLHQWV¶4R/ 17 
(Rabins et al., 1999), which has been considered invalid in the case of mild to moderate 18 
dementia (Trigg et al., 2007). DQOL is the scale developed exclusively to be administered to 19 
patients (Ready et al., 2004) and assesses feeling states and mood, which may fail to capture 20 
other QoL areas impact by the disease. Based on the conceptual framework and applicability, 21 
QOL-AD and DEMQOL are preferred in future trials of people with mild to moderate 22 
dementia, but if the study focuses more about health-related QoL, DEMQOL may be a better 23 
choice. Furthermore, as described previously, health utility scores, DEMQOL-Utility, can be 24 
generated from DEMQOL, which could be used to complement the generic utility instrument 25 
18 
 
in future cost-utility analysis (Mulhern et al., 2013), although its validity and responsiveness 1 
need further testing. 2 
 3 
Regarding the generic QoL measure, we identified 3 instruments that generate health utility 4 
scores and 7 other measures. EQ-5D is the most used health utility instrument, but it has been 5 
commented to lack sensitivity, especially in the area of mental health (Shah, 2016). 6 
Therefore, the 5-level EQ-5D (EQ-5D-5L) is suggested to be used because of its improved 7 
sensitivity and reduced ceiling effect. SF-36 and SF-12 are the mostly used generic QoL 8 
instruments, providing summary scores of health-related QoL and thus enabling comparisons 9 
across different diseases, population groups, and interventions (Patrick and Deyo, 1989). 10 
Although SF-36/SF-12 is increasingly used in patients undergoing routine operations, it may 11 
fail to observe the small but clinical important differences or changes in dementia study, 12 
which could be captured by disease-specific measures. Preferences for generic or disease-13 
specific measures usually depends on the purpose of the study (Patrick and Deyo, 1989); 14 
therefore, if a study aims not only to measure the QoL concepts covered by a generic 15 
measure, but also to capture the specific concerns related to dementia or cognitive 16 
impairment, we suggest to include both generic and dementia-specific measures in the same 17 
study.   18 
 19 
It should be noted that in previous trials in mild to moderate dementia (D'Amico et al., 2015, 20 
Banerjee et al., 2011), both DEMQOL and DEMQOL-Proxy were included. Self-rated and 21 
proxy-rated EQ-5D were also used together in several studies (Romeo et al., 2013, D'Amico 22 
et al., 2015, Hoffmann et al., 2016). Given the complexity of dementia, researchers suggest 23 
that both patient-reported outcomes and observable behaviour, which is based on proxy-24 
reporting, should be included in order to better measure the effects of interventions (Mulhern 25 
19 
 
et al., 2013). DEMQOL-Proxy has been shown to give complementary perspectives on QoL 1 
to DEMQOL (Smith et al., 2005) and thus the use of both measures together is recommend.  2 
:KDW¶VPRUHDt some point patients may be unable to meaningfully assess their own QoL, 3 
and under such circumstances, researchers have to rely on other sources such as proxy-4 
reporting. Proxy EQ-5D appears to be an acceptable source of data for QALYs (Devine et al., 5 
2014) and has been used in some studies. But due to the poor agreement between proxy 6 
scores and self-reported scores, they cannot be assumed to substitute for each other (Arons et 7 
al., 2013) and cost-effectiveness analyses using both approaches should be conducted. 8 
 9 
The limitation of this review should be mentioned. Since no quality assessment tool was 10 
available for this kind of review and the psychometric properties were not formally compared 11 
in this review, our approach necessarily involved subjective judgement.  12 
 13 
Conclusions  14 
 15 
There is a lack of firm evidence about the use of standardised instrument to collect resource 16 
use and QoL data in trials about interventions for dementia. Several useful resource use and 17 
quality of life measurement instruments have been identified by this review, which would 18 
contribute to the study design of future economic evaluation alongside clinical trials in 19 
dementia care. For resource use, CSRI was mostly used, but no studies have used RUD; for 20 
QoL, we recommend the inclusion of dementia-specific DEMQOL, generic SF-12, and health 21 
utility EQ-5D-5L, based on both self- and proxy-report.   22 
 23 
 24 
 25 
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Table 1. Characteristics of included studies 
Characteristics  Number (%) of trials, n=41 
Year of publication    
 2000-2005 6  (14.6%) 
 2006-2010 13 (31.7%) 
 2011-2017 22 (53.7%) 
Country   
 United States 12 (29.3%) 
 United Kingdom 10 (24.4%) 
 Australia  5 (12.2%) 
 Finland  2 (4.9%) 
 Netherlands  2 (4.9%) 
 Other (1 trial per country) a 10 (24.4%) 
Type of study   
 Pilot study 11 (26.8%) 
 RCT 30 (73.2%) 
Disease   
 Mild cognitive impairment only 13 (31.7%) 
 Dementia only 9 (22.0%) 
 Both  19 (46.3%) 
Intervention    
 Pharmacological  5 (12.2%) 
 Non-pharmacological  35 (85.4%) 
 Combined  1 (2.4%) 
a
 Other countries/regions include Brazil, Denmark, France, Germany, Hong Kong, Japan, Korea, Norway, 
Sweden and Switzerland. 
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Table 2. Number (%) of trials reporting QoL outcomes and measurement instruments 
 
Number (%) of trials, n=41 
Dementia-specific instruments    
4XDOLW\RI/LIHLQ$O]KHLPHU¶V'LVHDVH(QOL-AD) 22 53.7% 
Dementia Quality of Life questionnaire (DEMQOL) 4 9.8% 
Quality of Life in Late-stage Dementia (QUALID) 3 7.3% 
Alzheimer's Disease Related Quality of Life (ADRQL) 2 4.9% 
Dementia Quality of Life Instrument (DQOL)   1 2.4% 
Generic instruments    
Utility measures   
EuroQol 5-dimentison (EQ-5D) 5 12.2% 
15-dimentison (15D) 1 2.4% 
Health Utilities Index Mark 3 (HUI3) 1 2.4% 
Other measures   
36-item Short-Form (SF-36) 2 4.9% 
12-item Short-Form (SF-12) 1 2.4% 
12-item General Health Questionnaire (GHQ-12) 1 2.4% 
15-item Quality of Life Scales (QOLS) 1 2.4% 
Anamnestic Comparative Self-Assessment Scale (ACSA) 1 2.4% 
QOL Face Scale scores 1 2.4% 
Quality of Life Assessment-Patient (QLA-P) 1 2.4% 
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Table 3. Characteristics of quality of life  instruments used in eligible studies 
Instrument Conceptual basis Patient report (Yes/No) 
Proxy report 
(Yes/No) 
Patient 
population Subscales and items Response options Scoring 
Dementia-specific instruments       
Quality of Life in 
$O]KHLPHU¶V'LVHDVH
(QOL-AD) 
Domains validated 
during focus groups with 
people with dementia 
and caregivers 
Yes Yes Dementia and MCI 
13 items for patient version, 15 
items for proxy version: 
physical health; energy level; 
mood; living situation; memory; 
family; marriage; friends; self; 
ability to do chores and things for 
fun; money; and life as a whole 
4-point scales  
 
Score range 13-52 for 
patient-reported and 15-60 
for proxy-rated; high scores 
represent better QoL  
Dementia Quality of 
Life questionnaire 
(DEMQOL) 
Areas of QoL affected by 
a health condition Yes Yes 
Dementia and 
MCI 
5 domains (28 items for patient, 31 
items for proxy): 
daily activities and looking after 
self; health and well-being; 
cognitive functioning; social 
relationships; self-concept 
4-point Likert 
scales  
 
Score range 28-112 for 
DEMQOL and 31-124 for 
DEMQOL-Proxy; high 
scores indicate better QoL 
Quality of Life in 
Late-stage Dementia 
(QUALID) 
Affect and activity 
measures for use with 
late-stage dementia 
patients 
No Yes Severe dementia 
11 observable behaviours of 
observable activity and emotional 
states 
5-point Likert 
scales 
Score range 11-55; lower 
scores represent better QoL 
Alzheimer's Disease 
Related Quality of 
Life (ADRQL)  
Domains of QoL that 
their caregivers and 
experts identified as 
important 
No Yes Dementia and MCI 
5 domains (48 items): 
social interaction; awareness of 
self; feelings and mood; enjoyment 
of activities; response to 
surroundings 
4-point Likert 
scales 
 
Score calculated using a 
preference-based weighting 
approach; higher scores 
represent better QoL 
Dementia Quality of 
Life Instrument 
(DQOL)  
Feeling states and mood Yes No Dementia and MCI 
5 subscales (30 items): aesthetics; 
positive affect; absence of negative 
affect; belonging; and self-esteem 
5-point Likert 
scales 
Scores on 5 subscales 
without overall score; lower 
scores on negative affect and 
higher scores on the other 
subscales indicate better 
QoL 
 
Generic instruments        
EuroQol 5-
dimentison (EQ-5D) 
Health defined using a 
descriptive system in 
domains and levels for 
each domain 
Yes Yes Dementia and MCI 
5 domains: mobility; self-care; 
usual activities; pain/discomfort; 
and anxiety/depression 
3-level for each 
domain 
 
Scores calculated using 
social weights; range from -
0.594-1 (UK weights); 
higher scores reflects better 
health 
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15-dimentison (15D) 
Health defined using a 
descriptive system in 15 
dimensions 
Yes No MCI 
15 dimensions: mobility; vision; 
hearing; breathing; sleeping; eating; 
speech; excretion; usual activities; 
mental function; discomfort and 
symptoms; depression; distress; 
vitality; and sexual activity 
5 levels for each 
dimensions 
Scores calculated using 
social weights; range 0-1; 
higher scores reflects better 
health 
 
Health Utilities Index 
Mark 3 (HUI3) 
Health defined using a 
descriptive system in 
attributes and levels 
within each attribute 
No Yes Dementia and MCI 
8 attributes: hearing; vision; speech; 
ambulation; dexterity; emotion; 
cognition; and pain 
3-6  functional 
levels for each 
attribute 
Score range -0.36-1; higher 
scores reflects better health 
36-item Short-Form 
(SF-36) and 12-item 
Short-Form (SF-12) 
Health concepts that are 
relevant to patients from 
SDWLHQW¶VSHUVSHFWLYH 
Yes  No  MCI 
8 areas: physical functioning; role 
functioning; bodily pain; general 
health; vitality; social functioning; 
role-emotional functioning; and 
mental health 
2-6 levels for each 
question 
Summary scores, PCS and 
MCS, range from 0-100; 
higher scores reflects better 
health 
12-item General 
Health Questionnaire 
(GHQ-12) 
Psychiatric disorder Yes  No Dementia and MCI 
2 main areas (12 items): the 
inability to carry out normal 
functions; the appearance of new 
and distressing phenomena 
4-point scale Score range 0-36, lower indicate better health 
15-item Quality of 
Life Scales (QOLS) 
Items derived from a 
general public sample by 
researchers 
Yes No MCI 
5 domains (15 items): material and 
physical well-being; relationships 
with other people; social, 
community, and civic activities; 
personal development and 
fulfilment; and recreation 
7-point scale Score range 16-112; higher 
scores reflects better health 
Anamnestic 
Comparative Self-
Assessment Scale 
(ACSA) 
Subjective well-being 
defined in terms of the 
µEHVWWLPH¶YHUVXVWKH
µZRUVW WLPH¶LQOLIH 
Yes  No  MCI / 10-stage anchor 
scale  
An improvement in global 
scale score reflects higher 
quality of life 
QOL Face Scale  
Degree of general 
happiness in current 
daily life 
No Yes  MCI / 9-choice picture format  
Score range 1-9; higher 
scores indicate better QoL 
Quality of Life 
Assessment-Patient 
(QLA-P) 
%URDGDUHDVRISDWLHQW¶V
quality of life No Yes  Dementia  
10 categories: working; leisure; 
eating; sleeping; social contact; 
earning; parenting; loving; 
environment; and self-acceptance 
Anchor-point  Scale range 0-50; higher 
scores indicate better QoL 
*MCI: mild cognitive impairment 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
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Additional records identified 
through other sources  
(n = 6) 
Records after duplicates removed  
(n =1089) 
Records screened 
(n =1089) 
Records excluded 
(n = 1024 ) 
Full-text articles assessed 
for eligibility 
(n =  65) 
Full-text articles excluded, with reasons 
(n=24) 
x 4 protocol or descriptive articles 
x 6 about caregivers 
x 14 no instruments used 
Studies included in 
qualitative synthesis 
(n =41) 
Figure 1. PRISMA flow diagram identification, screening, eligibility and included articles. 
Appendix S1. Search terms for Ovid Medline 
 
1 exp dementia/ or exp alzheimer disease/ or exp cognitive impairment/ 
2 sensory impairment.ti,ab. 
3 1 or 2 
4 exp aged/ or exp frail elderly/ 
5 (older or old or elderly or senior or "over 65" or "65 year*").ti,ab. 
6 4 or 5 
7 Economics, Medical/ or Economics/ or Economics, Hospital/ or Economics, 
Nursing/ 
8 exp "Costs and Cost Analysis"/ 
9 Health Expenditures/ 
10 ("resource use" or "health care utilisation" or "health care utilization" or "resource 
utilisation" or "resource utilization").ti,ab. 
11 7 or 8 or 9 or 10 
12 "Quality of Life"/ 
13 Quality-Adjusted Life Years/  
14 ("health utility" or QALY).ti,ab. 
15 12 or 13 or 14 
16 11 or 15 
17 (intervention or program or promotion).ti,ab. 
18 Clinical Trial/ 
19 Feasibility Studies/ 
20 Pilot Projects/ 
21 (trial or feasibility or pilot).ti,ab. 
22 18 or 19 or 20 or 21 
23 3 and 6 and 16 and 17 and 22 
  
